Treatment Patterns in Hospitalized Hip Fracture Patients: An Interrupted Time-Series Analysis Around the New Fee for...

Despite high risk of secondary fracture, osteoporosis treatment rates following hip fracture remain low globally. In April 2022, Japan implemented a reimbursement policy for secondary fracture prevention in patients with hip fracture. We evaluated the impact of this policy on treatment patterns during acute hospitalization.

We conducted an interrupted time-series analysis using the Medical Data Vision database for patients aged ≥ 50 years hospitalized with hip fractures from April 2020 to March 2024. Primary outcome was osteoporosis medication treatment rate during hospitalization. Secondary outcomes included drug class distribution and use of medications categorized as recommended or proposed in preventing fractures according to Japanese guidelines. Segmented regression models were used to evaluate level and trend changes associated with policy implementation.

Among 71,632 eligible patients with hip fracture (mean age 84, 76% female), the interrupted time-series analysis revealed a significant immediate increase in treatment rates (level change [β₂] = 16%, 95% CI 13-19%, p < 0.001) following policy implementation, with continued monthly growth thereafter (sustained positive slope change [β₃] = 1% per month, p < 0.001). Use of medications both proposed and recommended in the guideline increased significantly for both (level change = 13%, p < 0.001 and level change = 8%, p < 0.001, respectively). Between 2020/21 and 2023/24, the use of bisphosphonates and active vitamin D₃ as monotherapy both increased, from 12% to 29% for each. Nevertheless, overall use of osteoporosis medications, especially non-bisphosphonate drugs, with proven fracture-prevention efficacy and those recommended by clinical guidelines remained low.

Japan's secondary fracture prevention reimbursement policy successfully improved in-hospital initiation of osteoporosis treatment among patients with hip fracture. Nevertheless, actual usage of osteoporosis medications with robust evidence for fracture prevention remains suboptimal. Effective prevention of secondary fractures and improved patient outcomes require appropriate medication selection, potentially facilitated by supportive policy measures.